导航阴性夜间血红素尿 (PNH) 景观
Gloria F Gerber1, Catherine M Broome2, Ilene C Weitz3
1Department of Medicine, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD.
Clinical advances in hematology & oncology : H&O
|July 1, 2025
概括
性夜间血红蛋白尿症 (PNH) 治疗方法正在发展. 新的上游补充抑制剂解决了血管内和血管外血解,为PNH患者提供了更好的结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阴性夜间血红蛋白尿 (PNH) 是一种罕见的克隆性造血干细胞疾病.
- 这种PNH的特征是补充介导的血液溶解性贫血,骨髓衰竭和血栓形成.
- 由于PIGA突变,糖酸氨基醇定补充剂调节蛋白减少或不存在.
研究的目的:
- 审查补充剂抑制剂对PNH的长期疗效和安全性.
- 讨论对PNH的上游补充抑制剂的开发和应用.
- 要突出在PNH中血管内和血管外血解的管理.
主要方法:
- 对临床试验数据和PNH补充抑制剂的现实世界证据的审查.
- 对终端补充抑制剂 (C5抑制剂) 和上游补充抑制剂的治疗结果的分析.
- 评估eculizumab,ravulizumab,crovalimab,pegcetacoplan,iptacopan和danicopan的安全性和疗效概况. 这三种药物中的一个是:
主要成果:
- 终端补充抑制剂 (例如,eculizumab,ravulizumab) 有效地管理血管内血解和血栓形成.
- 大约30%的服用C5抑制剂的患者经历了残留的血管外血液溶解.
- 上游补充抑制剂 (例如,佩格塞塔科普兰,伊普塔科潘) 在控制血管内和血管外血液溶解,改善血红蛋白水平和减少输血需求方面表现出有效性.
结论:
- 终端补充抑制剂已经改变了PNH管理,改善了生存和生活质量.
- 上游补充抑制剂为C5抑制剂的残留血液溶解患者提供了新的治疗选择.
- 需要结合疗法和进一步的现实世界数据,才能充分了解新型补剂抑制剂在PNH中的长期影响和安全性.
更多相关视频
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
17.2K
12:05Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
11.8K
相关概念视频
01:20Overview of Hematopoiesis
4.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.8K
01:21Hematopoiesis
5.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.7K
00:49The Blood-brain Barrier
48.9K
Overview
48.9K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K